APA (7th ed.) Citation

Oguchi, K., Irie, H., Ito, K., Fujioka, Y., Yamada, Y., Shimamura, T., . . . Iwasawa, Y. (2016). 57 - TPC-107, a next generation, HER2 selective covalent inhibitor demonstrates potent inhibition for activated mutations of HER2 while sparing EGFR inhibition. European Journal of Cancer, 69, S26. https://doi.org/10.1016/S0959-8049(16)32657-0

Chicago Style (17th ed.) Citation

Oguchi, K., et al. "57 - TPC-107, a Next Generation, HER2 Selective Covalent Inhibitor Demonstrates Potent Inhibition for Activated Mutations of HER2 While Sparing EGFR Inhibition." European Journal of Cancer 69 (2016): S26. https://doi.org/10.1016/S0959-8049(16)32657-0.

MLA (9th ed.) Citation

Oguchi, K., et al. "57 - TPC-107, a Next Generation, HER2 Selective Covalent Inhibitor Demonstrates Potent Inhibition for Activated Mutations of HER2 While Sparing EGFR Inhibition." European Journal of Cancer, vol. 69, 2016, p. S26, https://doi.org/10.1016/S0959-8049(16)32657-0.